08Mar 2025
Alzheimer’s Prognostic Covariates Improve Lecanemab Trial Efficiency

Alzheimer’s Prognostic Covariates Improve Lecanemab Trial Efficiency

This study evaluates Alzheimer's prognostic covariates (APCs) in lecanemab trials to reduce variability in treatment effect assessments. Using APCs derived from clinical and MRI data decreased variance by 19.1%, increased power to 90.2%, and reduced sample size by 27.2%. These findings highlight APCs as valuable tools for improving statistical power and efficiency in AD clinical trials.

  • #neurology

Like

Save

Share